Lemercier Jean-Luc M 4
4 · Edwards Lifesciences Corp · Filed May 6, 2024
Insider Transaction Report
Form 4
Lemercier Jean-Luc M
CVP, EMEA, Canada, Latin Amer
Transactions
- Exercise/Conversion
Performance Rights
2024-05-04−4,157→ 0 totalFrom: 2024-05-04Exp: 2028-05-03→ Common Stock (4,157 underlying) - Tax Payment
Common Stock
2024-05-03$85.06/sh−37$3,147→ 173,811.806 total - Tax Payment
Common Stock
2024-05-06$85.25/sh−259$22,080→ 177,709.806 total - Exercise/Conversion
Common Stock
2024-05-04+4,157→ 177,968.806 total
Footnotes (1)
- [F1]On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.